Is Gilead Sciences Too Dependent On These 2 Areas of Its Business?
Gilead is still, by and large, an HIV company.
Mindfully Curated
Gilead is still, by and large, an HIV company.
Things haven’t been this bad for the company in quite a long time.
The global infrastructure company highlighted the cleaner-burning fossil fuel in its recent letter to investors.
This Dividend Aristocrat can provide income investors with a safe and market-crushing 4.3% dividend yield.
Airbnb is firing on all cylinders and making its platform stand out more than ever before.
The e-commerce site thrived at the pandemic’s onset and is now experiencing the reversal of that trend.
An extended agreement with a leading pharmacy has boosted investor confidence.
These Buffett-inspired oil stock ideas offer alternative ways to jump into the oil patch.
Flexibility is a part of financial freedom.
The industrial giant managed to raise its full-year guidance while others are cutting it.
Investors seem to like the company’s soaring revenue. But the online real estate broker is still losing money.
Background checks on gun buyers are down more than 20% year to date.
These industry leaders deliver consistent profits and dividends for shareholders.
This promising business may present a multi-bagger opportunity for patient investors.
Here’s an honest look at how far Social Security will go in retirement.
The top streaming business is now open to a strategy that it has long avoided.
Booming sales of 5G smartphones will be a tailwind for these companies.
These big stock movements illustrate major market trends for investors.
These two growth stocks have been squashed in recent months, and now it’s time to buy.
Match Group is a rumored acquisition candidate. Could Facebook be the buyer?